/
ANVS
$1.86+$0.14 (+8.14%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$73.2M
43M shares
52-week range
$1.54 – $5.50
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
1.01%
Moderate
Price (6 mo)
Loading chart…
Change$-87.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $111.6K | $776.3K | $3.1M | $8.5M | $16.5M | $38.8M | $20.0M | $25.2M |
| Operating income | −$714.0K | −$1.6M | −$6.6M | −$14.5M | −$25.5M | −$45.0M | −$26.7M | −$29.7M |
| EBITDA | $66 | −$791.0K | $0 | −$14.5M | −$25.3M | −$56.2M | −$22.7M | −$28.9M |
| Net income | −$714.0K | −$991.0K | −$5.5M | −$14.5M | −$25.3M | −$56.2M | −$24.6M | −$28.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.16 | -0.17 | -0.87 | -1.90 | -3.10 | -6.23 | -2009.77 | -1.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-1.86 | $-1.86–$-1.86 | 1 |
| 2027 | $17M | $-1.55 | $-1.55–$-1.55 | 1 |
| 2028 | $51M | $-1.89 | $-2.00–$-1.77 | 2 |
| 2029 | $297M | $0.35 | $0.35–$0.35 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.84
Price
$1.86
Implied downside
-55%
Peer comparison
Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
www.annovisbio.com- Employees
- 7
- IPO / List date
- Jan 29, 2020
- HQ
- MALVERN, PA
Held by traders on TradeandTell
No one on the platform currently holds ANVS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 347,600 | $775.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANVS yet.
